2seventy Bio Inc Revenue Growth Rates (TSVT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
2seventy Bio Inc   (NASDAQ: TSVT)
 

TSVT's Revenue Growth by Quarter and Year

2seventy Bio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TSVT Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 22.94
FY 22.94





TSVT Revenue first quarter 2025 Y/Y Growth Comment
2seventy Bio Inc achieved in the first quarter 2025, above Company average Revenue rise of 84.39% year on year, to $ 22.94 millions.

Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 32 other companies have achieved higher Revenue growth. While 2seventy Bio Inc ' s Revenue jump of 84.39% ranks overall at the positon no. 205 in the first quarter 2025.


TSVT Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - -72.57 % -80.99 % 250.25 %
3rd Quarter September - 12.47 % -10.29 % -30.37 %
2nd Quarter June - -75.12 % 167.43 % 83.9 %
1st Quarter March 84.39 % -70.11 % 393.71 % -29.16 %
FY   - -62.27 % 9.7 % -

Financial Statements
2seventy Bio Inc 's first quarter 2025 Revenue $ 22.94 millions TSVT's Income Statement
2seventy Bio Inc 's first quarter 2024 Revenue $ 12.44 millions Quarterly TSVT's Income Statement


TSVT Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - -78.34 % -11.22 % 318.94 %
3rd Quarter September - 50.84 % -66.63 % -0.52 %
2nd Quarter June - -27.89 % -13.38 % 59.91 %
1st Quarter March 682.87 % 16.48 % -25.92 % -47.44 %
FY (Year on Year)   - -62.27 % 9.7 % -


Back to TSVT Growth rate Comparisons >> Back to TSVT Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #67
Overall #205

Revenue Y/Y Growth Statistics
High Average Low
393.78 % 31.86 % -80.98 %
(Sep 30 2023)   (Jun 30 2024)
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #67
Overall #205
Revenue Y/Y Growth Statistics
High Average Low
393.78 % 31.86 % -80.98 %
(Sep 30 2023)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

2seventy Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
683.94 % 75.52 % -78.38 %
(Mar 31 2025)  


TSVT's I. Quarter Q/Q Revenue Comment
2seventy Bio Inc achieved in the I. Quarter 2025 above company average sequential Revenue doubling of 682.87%, to $ 22.94 millions, from $2.93 millions in the fourth quarter.
TSVT is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Revenue quarter on quarter growth. While 2seventy Bio Inc 's Revenue growth quarter on quarter, overall rank is 37.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #18
Overall #37
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #18
Overall #37
Revenue Q/Q Growth Statistics
High Average Low
683.94 % 75.52 % -78.38 %
(Mar 31 2025)  


TSVT's I. Quarter Q/Q Revenue Comment
2seventy Bio Inc achieved in the I. Quarter 2025 above company average sequential Revenue doubling of 682.87%, to $ 22.94 millions, from $2.93 millions in the fourth quarter.
TSVT is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Revenue quarter on quarter growth. While 2seventy Bio Inc 's Revenue growth quarter on quarter, overall rank is 37.


2seventy Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 48.36 $ 37.86 $ 45.62 $ 44.12 $ 71.20
Y / Y Revenue Growth (TTM) -32.07 % -62.28 % -68.73 % -70.04 % -42.9 %
Year on Year Revenue Growth Overall Ranking # 2775 # 1175 # 15 # 5 # 17
Seqeuential Revenue Change (TTM) 27.74 % -17.01 % 3.4 % -38.03 % -29.07 %
Seq. Revenue Growth (TTM) Overall Ranking # 3615 # 3414 # 1823 # 379 # 169


Cumulative Revenue growth Comment
2seventy Bio Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2024. If the fiscal year would end in Mar 31 2025, 2seventy Bio Inc 's annual Revenue drop would be -32.07% year on year to $48 millions.

In the Healthcare sector 386 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1175 to 2775.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 387
Overall # 2775

Revenue TTM Y/Y Growth Statistics
High Average Low
808.23 %
 139.25 %
-70.04 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 490
S&P 500 # 3615
Cumulative Revenue growth Comment
2seventy Bio Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2024. If the fiscal year would end in Mar 31 2025, 2seventy Bio Inc 's annual Revenue drop would be -32.07% year on year to $48 millions.

In the Healthcare sector 386 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1175 to 2775.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 387
Overall # 2775

Revenue TTM Y/Y Growth Statistics
High Average Low
808.23 %
139.25 %
-70.04 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 490
S&P 500 # 3615




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TSVT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Prime Medicine Inc 146.02%$ 146.024 millions
Beyond Air Inc 145.11%$ 145.106 millions
Eton Pharmaceuticals Inc 140.63%$ 140.631 millions
C4 Therapeutics Inc 138.17%$ 138.170 millions
Springworks Therapeutics Inc 133.68%$ 133.681 millions
Lyell Immunopharma Inc 133.33%$ 133.333 millions
Generation Bio Co 114.91%$ 114.905 millions
Kymera Therapeutics Inc 114.83%$ 114.834 millions
Newamsterdam Pharma Company N v 112.56%$ 112.562 millions
Hims and Hers Health Inc 110.61%$ 110.608 millions
Eyepoint Inc 109.29%$ 109.286 millions
Bluebird Bio Inc 108.43%$ 108.432 millions
Legend Biotech Corporation107.52%$ 107.523 millions
Nuo Therapeutics Inc 106.49%$ 106.491 millions
Vyne Therapeutics Inc 106.12%$ 106.122 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________105.44%$ 105.439 millions
Xencor Inc104.61%$ 104.613 millions
Coya Therapeutics Inc 103.32%$ 103.318 millions
Alaunos Therapeutics Inc 100.00%$ 100.000 millions
Travere Therapeutics Inc 97.54%$ 97.544 millions
Krystal Biotech Inc 94.88%$ 94.880 millions
Avadel Pharmaceuticals Plc94.83%$ 94.830 millions
Scpharmaceuticals Inc 92.59%$ 92.593 millions
Tg Therapeutics Inc 90.40%$ 90.402 millions
Cytokinetics Incorporated89.10%$ 89.102 millions
Aclarion Inc 87.77%$ 87.769 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Neuronetics Inc 85.73%$ 85.733 millions
2seventy Bio Inc 84.46%$ 84.463 millions
Optinose Inc 83.27%$ 83.266 millions


About 2seventy Bio Inc Revenue Growth Rates (TSVT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: 2seventy Bio Inc (CIK 1860782).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001860782-25-000037
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: 2seventy Bio Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.